United States. Securities and Exchange Commission
Regenerx Biopharmaceuticals Inc. has submitted a Form 4 document to the U.S. Securities and Exchange Commission (SEC) on July 2, 2015. The filing reflects a change in ownership and relationship between the company and its officers, directors, or owners of more than 10% of its equity securities. The document
United States. Securities and Exchange Commission
French multinational pharmaceutical company Sanofi has published a US Securities and Exchange Commission (SEC) filing for its employee stock purchase, savings, and similar plans. The filing was made on June 26, 2015, and includes two accompanying documents. This SEC filing provides insights into Sanofi's employee benefit plans and
United States. Securities and Exchange Commission
Vertex Pharmaceuticals Inc. filed a U.S. Securities and Exchange Commission (SEC) form 4 on June 26, 2015, disclosing one document related to the company's financial activities. As a publicly-traded biotechnology company, Vertex Pharmaceuticals is subject to regular SEC filings, providing transparency into its financial dealings and corporate
United States. Securities and Exchange Commission
As more than half of all U.S. households own securities, Wall Street investors are increasingly dependent on the market to help secure their retirement and send their kids to college. However, this burden is compounded by the existing cap on civil monetary penalties, which in some cases can only
United States. Securities and Exchange Commission
The US Securities and Exchange Commission (SEC) has faced a significant setback in its use of administrative proceedings, following a ruling from the US District Court for the Northern District of Georgia that the manner of appointment of the SEC's administrative law judges (ALJs) is unconstitutional. This decision
United States. Securities and Exchange Commission
Medicines Co, a leading pharmaceutical manufacturer, has filed a U.S. Securities and Exchange Commission (SEC) Form 8-K on June 15, 2015, reporting a material event. The filing identifies the company's SIC code as 2834, Pharmaceutical Preparations, and provides contact information for the company's headquarters in
United States. Securities and Exchange Commission
Xoma Corp., a pharmaceutical company, made a U.S. Securities and Exchange Commission (SEC) filing on June 17, 2015. The filing, submitted under Form 4, was for a company identified by the SIC code 2834, which pertains to pharmaceutical preparations. The document, filed with the SEC, includes information about the
United States. Securities and Exchange Commission
Xoma Corp.'s recent SEC filing highlights the company's focus on developing pharmaceutical preparations. The filing, made on June 5, 2015, reveals the company's SIC code and contact information. This document submission underscores the importance of transparency in the financial industry, as it provides stakeholders
United States. Securities and Exchange Commission
According to a U.S. Securities and Exchange Commission (SEC) filing, Sunesis Pharmaceuticals Inc. reported significant corporate changes on June 10, 2015. The company is a pharmaceutical manufacturer with its main operations in South San Francisco, California. As a publicly-traded company, Sunesis Pharmaceuticals is required to submit regular financial statements
United States. Securities and Exchange Commission
Vivus Inc., a pharmaceutical company, has submitted a Form 4 filing to the U.S. Securities and Exchange Commission (SEC) as required by law. The filing, dated May 29, 2015, discloses changes in ownership and transactions involving the company's equity securities. As a publicly-traded company, Vivus Inc. is
United States. Securities and Exchange Commission
Xoma Corp., a pharmaceutical company with operations in Berkeley, CA, filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) on June 1, 2015, detailing the company's pharmaceutical preparation activities. As a company listed under the SIC code 2834, Pharmaceutical Preparations, Xoma Corp. is required
United States. Securities and Exchange Commission
Vertex Pharmaceuticals Inc. has made a regulatory filing with the Securities and Exchange Commission (SEC) detailing the company's pharmaceutical preparations, as per the source material. The filing, which was posted on May 21, 2015, provides information on the company's equity securities and ownership. According to the
